Author

Marty Schladen

Marty Schladen

Marty Schladen has been a reporter for decades, working in Indiana, Texas and other places before returning to his native Ohio. He's won state and national journalism awards for investigations into utility regulation, public corruption, the environment, prescription drug spending and other matters. He reports for the Ohio Capital Journal, part of the States Newsroom network of outlets covering state governments. Email: [email protected]

Biden administration announces ‘comprehensive’ plan to fix high drug prices

By: - September 17, 2021

The U.S. Department of Health and Human Services last week issued its plan to address high drug prices as part of President Joe Biden’s push to take on anticompetitive practices across the economy. But while it addressed in detail abusive practices by drugmakers, it was a lot more superficial about the practices of much-larger corporations that serve […]

In court, drug middlemen fight to limit access to pharmacies for insured patients

By: - September 8, 2021

In the first test of a 2020 U.S. Supreme Court ruling, drug middlemen last week argued that federal law gives them a crucial right to limit what pharmacies patients with health insurance can use — or at least make it more expensive if patients get their medicine at a shop that isn’t preferred by the […]

Antitrust concerns are increasing on Capitol Hill. Advocates say they should extend to drug pricing.

By: - June 2, 2021

Congress is beginning to take notice as corporations become increasingly dominant in one or more marketplaces. It’s investigating whether Amazon, Google, Apple and Facebook are engaging in anticompetitive practices. And Sen. Amy Klobuchar, D-Minn., just published a book about the need to revive the government’s antitrust powers. But if this is to be a new era of trust-busting, advocates […]

Federal probe of drug middlemen urged

By: - May 11, 2021

By Marty Schladen After years of accusations, a bipartisan group in the U.S. Senate wants federal regulators to investigate whether drug middlemen and their parent companies are rigging the system to raise prices and pad their pockets. Sens. Chuck Grassley, R-Iowa, and Maria Cantwell, D-Wash., last month filed legislation that would require the federal trade commission […]

Supreme Court hears arguments over states’ ability to regulate drug costs

By: - October 8, 2020

How much leeway states have to control drug middlemen was at the heart of arguments Tuesday before the U.S. Supreme Court.  The case, Rutledge v Pharmaceutical Care Management Association, pits 47 state attorneys general (including Virginia’s) and the U.S. Solicitor General against an industry group representing three of the 20 largest corporations in the United States.  […]

Big fight over drug pricing heads to the Supreme Court

By: - October 6, 2020

A years-long fight over whether states have the authority to regulate important aspects of drug pricing will be argued before the U.S. Supreme Court Tuesday morning. At issue is whether prescription middlemen, known as “pharmacy benefit managers,” will have to bow to state authority over a huge swath of their business or if federal law […]

‘14,000 attempts.’ Balky technology, expiring benefits worry workers, state leaders.

By: - July 31, 2020

Congress is continuing to squabble over whether to extend a federal supplement to unemployment insurance and if they do, by how much. But as they argue over whether to continue the supplement at $600 a week or some fraction of that, out-of-work Americans are left to worry whether they can survive on state benefits that […]